Armistice Capital LLC Trims Stock Position in Aspira Women’s Health Inc. (NASDAQ:AWH)

Armistice Capital LLC decreased its position in shares of Aspira Women’s Health Inc. (NASDAQ:AWH) by 59.6% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 468,000 shares of the company’s stock after selling 689,000 shares during the quarter. Armistice Capital LLC’s holdings in Aspira Women’s Health were worth $697,000 as of its most recent filing with the SEC.

Separately, B. Riley Wealth Advisors Inc. boosted its position in shares of Aspira Women’s Health by 43.1% in the 4th quarter. B. Riley Wealth Advisors Inc. now owns 179,371 shares of the company’s stock valued at $732,000 after purchasing an additional 53,997 shares during the period. 12.19% of the stock is currently owned by hedge funds and other institutional investors.

Aspira Women’s Health Stock Performance

NASDAQ AWH opened at $0.82 on Friday. Aspira Women’s Health Inc. has a one year low of $0.74 and a one year high of $6.01. The firm has a market cap of $13.19 million, a PE ratio of -0.57 and a beta of 1.48. The firm’s fifty day moving average is $1.08 and its two-hundred day moving average is $2.04.

Aspira Women’s Health (NASDAQ:AWH) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.04. The company had revenue of $2.42 million for the quarter, compared to analysts’ expectations of $2.60 million. During the same period in the prior year, the company earned ($0.28) earnings per share. Research analysts predict that Aspira Women’s Health Inc. will post -1.26 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on AWH. Alliance Global Partners dropped their price target on Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating on the stock in a research note on Wednesday, August 14th. StockNews.com upgraded shares of Aspira Women’s Health from a “sell” rating to a “hold” rating in a research report on Tuesday.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.